Give Online: Help shape patient care for generations to come.

Appointments

877.463.2010

Request an Appointment

Questions

866.293.7866

Contact us with Questions

International: + 001 954.659.5080

Expand Content

Cancer Research

Cleveland Clinic Florida's Cancer Research staff is dedicated to providing patients innovative therapies through clinical research trials which include new targeted agents and therapies. Cancer specialists from The Maroone Cancer's Departments of Hematology and Oncology serve as principal investigators for the trials, working closely with the research staff and collaborating with the world-renowned Taussig Cancer Institute at Cleveland Clinic in Ohio. Cleveland Clinic Florida also participates in many clinical trials with the National Cancer Institute.

For more information about our clinical trials, please contact:
Abel Rodriguez, Clinical Research Supervisor
Phone: 954.487.2258
Email: RODRIGA2@ccf.org

Reviewed: 09/15

Areas of Cancer Clinical Trials

Brain Cancer
A Randomized Phase III Trial Of Memantine And Whole-Brain Radiotherapy With Or Without Hippocampal Avoidance In Patients With Brain Metastases
  • Trial Description
  • Sponsor Study Number: NRG-CC001
  • Cleveland Clinic Study Number: IRB 15-1581
  • Principal Investigator: John F. Greskovich, MD
Breast Cancer
A Phase IB/II Dose-Escalation Study Evaluating The Combination Of Trastuzumab Emtansine (T-Dm1) With Neratinib In Women With Metastatic HER2-Positive Breast Cancer
  • Trial Description
  • Sponsor Study Number: NSABP FB-10
  • Cleveland Clinic Study Number: IRB 14-1481
  • Principal Investigator: Thomas A. Samuel, MD
A Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating The Use Of Adjuvant Endocrine Therapy +/- One Year Of Everolimus In Patients With High-Risk, Hormone Receptor-Positive And Her2/Neu Negative Breast Cancer
  • Trial Description
  • Sponsor Study Number: SWOG S1207
  • Cleveland Clinic Study Number: IRB 13-640
  • Principal Investigator: Thomas A. Samuel, MD
A Randomized Phase III Trial Of Endocrine Therapy Plus Entinostat/Placebo In Patients With Hormone Receptor-Positive Advanced Breast Cancer
  • Trial Description
  • Sponsor Study Number: ECOG E2112
  • Cleveland Clinic Study Number: IRB 16-194
  • Principal Investigator: Thomas A. Samuel, MD
NRG-BR003 - A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
  • Trial Description
  • Sponsor Study Number: NRG-BR003
  • Cleveland Clinic Study Number: IRB 15-1653
  • Principal Investigator: Elizabeth Stone, MD
A Phase III Study Evaluating Palbociclib (Pd-0332991), a Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor in Patients With Hormone-Receptor- Positive, Her2-Normal Primary Breast Cancer With High Relapse Risk After Neoadjuvant Chemotherapy
  • Trial Description
  • Sponsor Study Number: NSABP B54-I (PENELOPE) GBG 1115
  • Cleveland Clinic Study Number: IRB 15-1373
  • Principal Investigator: Thomas Samuel, MD
Molecular Mechanisms Involved in Cancer Predisposition
  • Cleveland Clinic Study Number: IRB 8458
  • Principal Investigator: Charis Eng, MD
Gastrointestinal
SWOG S1505 - A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
  • Trial description
  • Sponsor Study Number: SWOG S1505
  • Cleveland Clinic Study Number: IRB 15-1472
  • Principal Investigator: Timmy Nguyen, MD
Genitourinary
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
  • Trial description
  • Sponsor Study Number: SWOG S1314
  • Cleveland Clinic Study Number: IRB 14-1443
  • Principal Investigator: Bruno Bastos, MD
Head & Neck Cancer

Please check back for upcoming trials.

Lung Cancer
Adjuvant Lung Cancer Enrichment Market Identification and Sequencing Trial (ALCHEMIST): A screening trial for A081105 and E4512
Randomized Double Blind Placebo Controlled Study of ERLOTINIB or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
A Phase III Double-Blind Trial for Surgically Resected Early State Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Prostate Cancer
Androgen Deprivation Therapy And High Dose Radiotherapy With Or Without Whole-Pelvic Radiotherapy In Unfavorable Intermediate Or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
  • Trial description
  • Sponsor Study Number: RTOG 0924
  • Cleveland Clinic Study Number: IRB 11-033
  • Principal Investigator: John F. Greskovich Jr., MD
Solid Tumor Cancer
An Open-Label, Multicenter, Global Phase II Basket Study Of Entrectinib For The Treatment Of Patients With Locally Advanced Or Metastatic Solid Tumors That Harbor Ntrk1/2/3, Ros1, Or ALK Gene Rearrangements
  • Trial description
  • Sponsor Study Number: STARTRK-2 / IGNT1Y15
  • Cleveland Clinic Study Number: IRB 16-004
  • Principal Investigator: Arun Nagarajan, MD